Dexcom (Nasdaq:DXCM) today announced findings from a study demonstrating the benefits of its G7 CGM in type 2 diabetes. The CONNECT study evaluated the current-generation G7 continuous glucose monitor (CGM) in people with type 2 diabetes not using insulin. It compared this population to a routine care control group using self-monitoring of blood glucose. Researchers shared […]
Clinical Trials
Abbott studies reinforce DKA opportunity following dual sensor milestone
Abbott (NYSE:ABT) today announced new clinical data highlighting the importance of managing diabetic ketoacidosis (DKA). The medtech giant shared findings from multiple studies at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans that demonstrate sharp increases in DKA-related hospitalizations across all age groups with type 1 and type 2 diabetes nationwide. Abbott […]
Insulet data backs Omnipod 6, fully closed-loop AID systems
Insulet (Nasdaq:PODD) today announced new clinical findings for its next-generation Omnipod 6 and fully closed-loop algorithm. The company shared results from its STRIVE pivotal trial and EVOLUTION 3 feasibility study. Investigators presented the outcomes at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. Findings demonstrated meaningful improvements in glucose control for people […]
Tidepool data highlights automated insulin delivery algorithm enhancements, women’s health initiative
Tidepool has new clinical insights and research initiatives related to diabetes management and automated insulin delivery (AID) technology. Palo Alto, California-based Tidepool is a non-profit diabetes data management group. It developed the FDA-cleared Tidepool Loop, a “do-it-yourself” (DIY) AID system. The hybrid, closed-loop AID app has compatibility with multiple insulin pumps and continuous glucose monitors. […]
MannKind shares more data backing inhaled insulin
MannKind (Nasdaq:MNKD) today announced new clinical findings for its Afrezza inhaled insulin powder and Furoscix furosemide injection. The company shared outcomes at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. MannKind’s Afrezza (insulin human) inhalation powder is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to […]
PharmaSens enrolls first patient in feasibility study for all-in-one automated insulin patch pump
PharmaSens said today that it enrolled the first patient in a clinical feasibility study of its all-in-one automated insulin patch pump system. The all-in-one pump pairs the Niaa insulin patch pump with a continuous glucose monitor (CGM) made by SiBionics. The companies announced a collaboration aimed at developing the all-in-one solution last year. Their all-in-one wearable […]
MIT, Apollon say needle-free CGM matched accuracy of leading sensors in study
Apollon and an MIT lab today shared clinical findings demonstrating the accuracy of their non-invasive continuous glucose monitor (CGM) device. Boston-based Apollon and MIT’s Laser Biomedical Research Center (LBRC) published their findings from the peer-reviewed clinical study in the Journal of Diabetes Science and Technology. Outcomes demonstrated that a compact, non-invasive CGM device based on band-pass […]
Medtrum data highlights time in range with automated insulin delivery system
Medtrum said that a study of its automated insulin delivery (AID) technology demonstrated increased time in range for people with diabetes. In 20 adults with type 1 diabetes, investigators evaluated the performance of the Medtrum A8 TouchCare in AID mode over three months. Findings included more time in range (70-180 mg/dL), increasing from 59.08% to […]
New data backs MiniMed 780G pump, SmartGuard algorithm across CGM types
MiniMed (Nasdaq:MMED) today shared findings from a new randomized crossover study backing the use of its 780 automated insulin pump. Findings demonstrated virtually identical glycemic outcomes for users of the pump across two different continuous glucose monitors (CGMs). Investigators published data today in Diabetes Technology & Therapeutics. MiniMed says outcomes reinforce that its automated insulin […]
Reflow Medical has positive data for coronary drug-eluting stent
Reflow Medical today announced the first six-month clinical results from a study of its Spur Elute sirolimus-eluting retrievable stent system. San Clemente, California-based Reflow designed its stent system to transfer a proprietary drug formulation to the diseased lesion without leaving a permanent metallic implant behind. The device’s retrievable scaffold therapy creates channels to increase the […]
